NCT Number: NCT02800824
Bioequivalence Study of Budesonide Rectal Aerosol Foam and Uceris® Rectal Aerosol Foam
To evaluate the bioequivalence between the Test Product Budesonide rectal aerosol foam and Reference Product Uceris® rectal aerosol foam after a single-dose in healthy subjects
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy, non-smoking, male and female subjects, 18 years of age or over.
- No clinically significant findings in vital signs measurements or 12-lead electrocardiogram (ECG) or abnormal laboratory values.
- Have no significant diseases.
- Willing to use an acceptable, effective method of contraception.
- Informed on the nature of the study and have agreed to and are able to read, review and sign all consent documents.
- Have no clinically significant findings from a physical examination.
Exclusion criteria
- Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results
- Known history or presence of hypersensitivity or idiosyncratic reaction to budesonide, any other components of the drug products, or any other drug substances with similar activity or sodium phosphate
- History or presence or of diabetes mellitus, glaucoma or cataracts, hypertension, or osteoporosis
- History of drug or alcohol addiction requiring treatment.
- History of malabsorption within the last year.
- Presence of hepatic or renal dysfunction.
- Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
- Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
Treatment and study plan
Uceris
DrugPrimary outcomes
-
Maximum observed plasma drug concentration (Cmax)
Time frame: 24 hours
-
AUC from time 0 extrapolated to infinity (AUC0-∞)
Time frame: 24 hours
-
AUC from time 0 to 24 hours (AUC0-24)
Time frame: 24 hours
Sponsors and collaborators
Lead sponsor
Padagis LLC
Industry
Registry information
Important dates
- Primary completion
- 2016
- First posted
- Jun 15, 2016
- Registry last updated
- Jan 13, 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
NCT07232732
Body Weight, Healthy
Daytona Beach, Florida, United States
View Trial Details3D Foot Scanning and Customized 3D-Printed Foot Orthotics to Reduce Pressure on the Feet of Healthy Adults
NCT07781618
Healthy
Bruges, West-Flanders, Belgium
View Trial DetailstDCS of the Primary Motor Cortex to Improve Implicit Motor Sequence Learning in Parkinson's Disease
NCT04606979
Basal Ganglia Diseases, Brain Diseases
Brussels, Brussels Capital, Belgium
View Trial DetailsEstablish the Role of Premotor and Motor Cortices in tDCS-facilitated Speech Motor Learning
NCT05804344
Healthy
New York, United States
View Trial Details